About UCB
UCB is a company based in Brussels (Belgium) founded in 1928. UCB has completed 9 acquisitions, including Be4, Element Genomics and Engage Therapeutics. UCB operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Brussels, Belgium
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$301.94 K (USD), Grant
Jan 01, 2020
-
Investors
European Union
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Be4
& 8 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of UCB
Unlock access to complete
Software Development Team
219 people
Leadership Team
92 people
Head Team
57 people
Global Team
39 people
Senior Team
36 people
Operations Team
36 people
Product Management Team
34 people
Human Resources and Administration
22 people
Unlock access to complete
Funding Insights of UCB
Investors in UCB
UCB has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Paul Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Functions as a diversified investor in secondary markets.
|
Locked | Locked | Locked |
Investor details for UCB
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by UCB
UCB has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Be4, Element Genomics and Engage Therapeutics.
Investment portfolio details for UCB
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of gene therapy to treat neurodegenerative diseases
|
Locked | Locked | 2019 | Locked | |
|
Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures
|
Locked | Locked | 2017 | Locked | |
|
An epigenomic editing platform is developed to identify drug targets.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for UCB
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - UCB
Detailed financials for UCB
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ucb Comparisons
Peer comparison for UCB
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of UCB
UCB operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of UCB
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ucb
Complete news archive for UCB
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UCB
UCB was founded in 1928 and raised its 1st funding round 81 years after it was founded.
UCB is headquartered in Brussels, Belgium. It is registered at Brussels, Brussels-capital Region, Belgium.
UCB was founded in 1928 and is headquartered in Brussels, Belgium. Focus is placed on the pharmaceutical sector, where therapies for immunological and neurological disorders are developed. Operations encompass the creation and distribution of medications such as Briviact, Vimpat, and Keppra for epilepsy treatment; Neupro for Parkinsons disease; and Cimzia for rheumatoid arthritis. Additional products are maintained in the portfolio to address related conditions globally.
UCB's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
UCB has made 9 acquisitions, including Be4, Element Genomics, and Engage Therapeutics.
UCB has 2 investors. Key investors include European Union, and Paul Capital.